Here's why the Cynata (ASX:CYP) share price is rising today

This biotechnology company has signed an agreement.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cynata Therapeutics Limited (ASX: CYP) share price is in the green today following news of a company deal.

Shares in the biotechnology company are up 4.1%, trading at 50 cents at the time of writing.

Let's look at what might be impacting the Cynata share price today.

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

What did the company announce?

Cynata advised it was entering a manufacturing services agreement with the Wisconsin-based Fujifilm Cellular Dynamics (FCDI).

The agreement will enable FCDI to manufacture stem cell technology for Cynata to use in clinical trials and potential commercialisation. These stem cells are derived from induced pluripotent stem cells.

Cynata is an Australian-based company that is developing therapies to treat human disease using its Cymerus therapeutic stem cell technology. This includes its lead product CYP-001, which is at the planning stage for a phase 2 clinical trial.

FCDI is a global developer of human-induced pluripotent stem cell technologies.

What did management say?

Commenting on the agreement, Cynata chief operating officer Dr Killian Kelly said:

Ultimately, we foresee FCDI manufacturing product for our growing pipeline of clinical trials in high value indications and potentially for commercial use.

This provides a turn-key manufacturing solution that our future corporate partners may avail themselves of.

Importantly, FCDI has also confirmed a strong commitment to our relationship by agreeing to extending the voluntary escrow over their shares in Cynata.

Cynata initially flagged the deal to the market in September.

Now the deal is sealed, the companies will set up a manufacturing process for the Cymerus stem cell technology at the FCDI's US base.

Cynata share price snapshot

The Cynata share price has plummeted this year, down nearly 28% since January.

In contrast, the S&P/ASX 200 Index (ASX: XJO) is returning nearly 12% this year to date.

The company's shares have lifted more than 11% in the past five days alone.

The company has a market capitalisation of around $71 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Test Only

Pacific Edge FY26: Loss widens but Medicare draft boost lifts outlook

Pacific Edge’s FY26 loss grew, but US Medicare draft coverage for its diagnostic tests supports a more positive outlook going…

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Why I'd buy CSL, Cochlear, and Pro Medicus shares

These are three ASX healthcare shares I would be happy to own for years.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Earnings Results

Sonic Healthcare share price in focus on FY26 profit jump and digital push

The healthcare company is paying total dividends of $1.08 per share in FY 2026.

Read more »

A man closely watches a clock.
Healthcare Shares

CSL shares are flying higher. Is it too late to buy?

CSL must now deliver faster earnings growth to justify its rally.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress

The radiopharmaceuticals company has handed down its half-year results this morning.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Earnings Results

Medibank FY26 earnings: Profit and dividend rise

The health insurance giant has released its full-year results this morning.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

How much are CSL shares worth? 4 brokers have their say

There are a wide range of views on this stock.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

CSL shares: 1 number that investors shouldn't ignore

This one number has me rethinking a CSL investment.

Read more »